New Jersey Headlines

Creative Biolabs Releases Three Antibody-drug Conjugation Strategies

 Breaking News
  • No posts were found

Creative Biolabs Releases Three Antibody-drug Conjugation Strategies

March 26
23:53 2019

New York, March 26 With years of experience in antibody-drug conjugates (ADCs) development, Creative Biolabs releases three different antibody-drug conjugation strategies to support global clients who are looking for efficient approaches for the development of site-specific ADCs.

 

Designing of an ADC is an elaborate process that involves careful planning, meticulous execution, and intensive trouble-shooting. Effective conjugation approaches will greatly increase the chance to generate highly customized ADCs in a timely and cost-efficient way. Therefore, depending on a deep understanding of conjugation chemistry, Creative Biolabs offers lysine-based conjugation strategy, cysteine-based conjugation, and carbohydrate-based conjugation.

 

1 Lysine-based conjugation

In ADC development, lysine conjugation is one of the most widely used non-specific conjugation strategies, which occurs on reactive amine side chains of lysine residues due to their good nucleophilicity. It is a simple process without requiring any form of antibody engineering or modification, suitable for the conjugation to both the Fab region and full-length IgG. Multiple conjugation sites enable the sufficient loading of payload drugs and its high chemical versatility can incorporate a variety of cytotoxic agents into antibodies.

 

2 Cysteine-based conjugation

Cysteine residues serve essential roles in protein structure and function due to their highly reactive thiol side chains that form inter or intra molecular di-sulfide bonds to enable correct protein folding and provides an appealing route for conjugating toxic agents to antibodies. There exist two kinds of cysteine-based conjugation strategies. Conjugation based on inter-chain cysteines generates ADCs with heterogeneous conjugation sites and a different number of drugs attached, resulting in a drug to antibody ratio (DAR) ranging from 0, while conjugation based on engineered cysteines, designated as EnCys-mAb, generates antibody-drug conjugates with improved homogeneity. Besides the advantages of easy operation and site-specific ability, cysteine conjugation offers flexible choices for generating either non-specific or site-specific ADCs.

 

3 Carbohydrate-based conjugation

Carbohydrate-based conjugation is unlikely to impair the antigen binding affinity and potentially serves as an excellent alternative for site-specific antibody-drug conjugate (ADC) generation. There are three elaborate strategies in Creative Biolabs to target carbohydrate moiety for the conjugation of payload drugs: (1) glycan chemical oxidation, (2) glycan enzymatic and chemo-enzymatic modification, and (3) carbohydrate moiety metabolic engineering. These strategies are suitable for the conjugation to glycosylated full-length IgG without reducing antigen binding affinity, and can be achieved by versatile approaches, including chemical, enzymatic, chemo-enzymatic, and metabolic engineering methods.

 

Aiming at helping clients with various ADC development projects, Creative Biolabs provides the most comprehensive antibody modification and conjugation strategies in a timely and cost-efficient manner. More details can be found at https://www.creative-biolabs.com/adc

 

 

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

 

 

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/adc

Categories